ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / WOK
NVNO (33) SNOA (34) XAIR (30) TNON (30) ⌘ Pro Terminal →

WORK Medical Technology Group LTD (Class A) (WOK) — RQD Stock Rating Cockpit

$1.00 -9.09% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.98

WORK Medical Technology Group LTD (Class A) (WOK) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY) →
ROARABLE D • SELL / AVOID Cap $4.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on WOK Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is WOK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, WORK Medical Technology Group LTD (Class A) (NASDAQ: WOK) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $1.00 (-9.09% 1D, market cap $4.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, WOK ranks #257 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does WOK compare to NVNO and SNOA in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), WOK carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NVNO (enVVeno Medical Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while NVNO leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for WOK?
▼

Per WOK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001929783), WORK Medical Technology Group LTD (Class A) generated $0 in revenue, -$1.1M in net income, and $4.9M in free cash flow against $33.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.98 (-1.83%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510051
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (16)Whales (3)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-3% Base Target
$87780 Bull$1 Base$1 Bear
📬 FREE WOK RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for WOK)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (51/100 Composite)
🔍 WHY WOK SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (31% of score)

SEC XBRL FY 2025 (10-K): 0.1% FCF Margin ($4.9M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
59
Grade C$1.39-17.3% Next Q
Q2 (-2Q)
56
Grade C$1.15+1.7% Next Q
Q3 (-1Q)
54
Grade C-$1.17-14.5% Next Q
Current
51
Grade D$1.00-1.3% Hist 90D α
Trajectory: C (59) → D (51)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a WOK Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While WOK currently carries a cautious 51/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.66) and Max Pain ($1.05) forces dealer call-delta covering toward $87,780.00.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $WOK• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “WOK Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 51%NO 49%Trade / Inspect Odds →
RSI-14 MOMENTUMOVERSOLD (<32)
31.530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
4 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $1$1.00H: $83,600
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (steady margins and healthy balance-sheet cushion).

Factor Grade: B+RQD 16 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on WOK

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (80)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (37)

12/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like WOK
  • ✓Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring WOK)

  • ✓Walkthrough of WOK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
WOK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -99.27%▲ RESISTANCE BREAKOUT
2026-11-03O $1.10H $1.10L $1.00C $1.00VOL 61.2K
RES: $0.82SUP: $0.98SMA50: $1.66SMA200: $60.94
$216,084.8$157,520.1$98,955.3$40,390.5$-18,174.28RES $0.82SUP $0.98$1.002026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

WOK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 WOK Butterfly Map → + Track WOK →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on WOK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for WOK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for WOK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (WOK)

Health Care Rank #257 of 1016 ⚔️ NVNO vs WOK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (WOK vs. NVNO, SNOA, XAIR, TNON)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, WORK Medical Technology Group LTD (Class A) (WOK) ranks #257 by composite RQD confidence (51/100, grade D) and #954 by equity capitalization ($4.5M). Within this direct 5-issuer industry benchmark cohort, XAIR leads on earnings valuation at 112.1x trailing P/E, while NVNO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. WOK currently leads its immediate peer cohort in composite quantitative strength at 51/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
WOK ACTIVE
WORK Medical Technology Group LTD (Class A)
D 51/100 — — — -9.09% $4.5M Benchmark Subject
NVNO
enVVeno Medical Corporation
E 33/100 — — -35.0% -4.13% $4.7M /nvno-vs-wok →
SNOA
Sonoma Pharmaceuticals Inc.
E 34/100 — 38.0% -35.0% -8.33% $5.3M /snoa-vs-wok →
XAIR
Beyond Air Inc.
E 30/100 112.1x 3.3% -35.0% -3.03% $3.7M /xair-vs-wok →
TNON
Tenon Medical Inc.
E 30/100 — 59.8% -35.0% -10.48% $5.5M /tnon-vs-wok →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001929783

In its most recent audited fiscal period (FY2025, filed 2025-09-30), WORK Medical Technology Group LTD (Class A) (WOK) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$1.1M, operating cash flow of $6.2M, and free cash flow of $4.9M (+142.9% YoY). On the balance sheet, WOK closed FY2025 with $33.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-09-30 $0 -$1.1M $6.2M $4.9M $33.2M —
FY2024 (FY) 2024-09-30 $0 -$3.5M -$2.2M -$11.5M — —
FY2023 (FY) 2023-09-30 $0 $112.0K $2.2M $2.2M — —

3. WOK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is WOK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, WORK Medical Technology Group LTD (Class A) (NASDAQ: WOK) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $1.00 (-9.09% 1D, market cap $4.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, WOK ranks #257 in composite RQD confidence.

How does WOK compare to NVNO and SNOA in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), WOK carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, NVNO (enVVeno Medical Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M) and SNOA (Sonoma Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while NVNO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for WOK?

Per WOK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001929783), WORK Medical Technology Group LTD (Class A) generated $0 in revenue, -$1.1M in net income, and $4.9M in free cash flow against $33.2M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is WOK trading relative to its 50-day, 200-day, and 52-week technical levels?

WOK last traded at $1.00 (-9.09% on volume of 61,191 shares), positioning the stock -39.76% below its 50-day simple moving average ($1.66) and -98.36% below its 200-day simple moving average ($60.94). Across its 52-week range of $1.00 to $83,600.00, WOK sits at the 0.0% percentile with a 14-day RSI of 31.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.13).

WOK Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell WOK stock right now?

WORK Medical Technology Group LTD (Class A) (WOK) currently earns a Roarable Rating of D (Sell — SELL) with 51/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is WOK's 12-month price target and RQD AI Jury consensus?

WOK's 12-month base price target is $0.97 (range $0.76 to $87780), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: WOK RQD Cockpit WOK 12M Forecast WOK Earnings & Move WOK Dividends & DRIP WOK Insiders & 13F WOK Whale Options WOK Profit Sankey WOK News & Why
ROARABLE RATING BRIEF • RQD 51/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

WOK — WORK Medical Technology Group LTD (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:53:22Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, WOK scores 51 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The score is built from five pillars:

  • Fundamental Cash Engine: 16 / 20. The rating cites ROIC of 0% and FCF yield of 0%. For a prospective investor, this means the source data shows no measurable return on invested capital and no free-cash yield relative to the share price.
  • Whale 13F Flow: 3 / 20. This pillar, covering institutional accumulation and options positioning, is the weakest in the set, indicating little supportive institutional flow in the source data.
  • Insider Conviction: 9 / 20. This pillar reflects SEC Form 4 and Congressional PTR cluster flow, and scores below midpoint.
  • Macro Regime Fit: 10 / 20. The rating cites Beta of 1.0 and sector sensitivity; the stock carries no reduced market-sensitivity advantage per the source.
  • Forensic Balance Sheet: 13 / 20. The rating cites Altman Z of 2.5, Piotroski F of 4/9, and Debt/Equity of 0.5. These are mid-range readings rather than a clear strength.

Taken together, the rating frames WOK as a name where the cash-generation and institutional-flow signals are weak, with the balance-sheet pillar providing the most support. Tradeoffs for a prospective investor include the very low share price ($1.1), a $4.9M market capitalization, and a 52-week range of $1 - $83600, which the source data presents without further explanation. This is an analytical framing, not personalized advice.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025 (filed 2025-09-30)$0.0M$0.0M$-1.1MN/A$4.9MN/AN/A
FY 2024 (filed 2024-09-30)$0.0M$0.0M$-3.5MN/A$-11.5MN/AN/A
FY 2023 (filed 2023-09-30)$0.0M$0.0M$0.1MN/A$2.2MN/AN/A

Per the SEC financials, reported revenue and operating income are $0.0M in each period, and net margin, gross margin, and operating margin are each 0%. Per the market data, ROIC is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 4/9, and Debt/Equity is 0.5. Cash and debt balances are N/A in the financials, so the source data does not give a full balance-sheet picture beyond these ratios.

Recent Catalysts & News Wire Analysis

Per the recent news feed, all five items are tagged to WOK with a YELLOW light and a MARKET WIRE impact label:

  • A Yahoo! Finance Canada item, published 1h ago, covering market action, institutional positioning, and fundamental catalysts.
  • A report from siam.in, published 3h ago, headlined as WOK holding flat at $1.11 with traders watching range boundaries.
  • A TradingKey item, published 6h ago, on unusual volume and volume spikes.
  • A Yahoo Finance Australia item, published 9h ago, covering price and history.
  • A TradingKey item, published 12h ago, on 52-week high stocks.

The news items describe market activity and price behavior but do not identify a specific fundamental catalyst. Risk watch items per the data include the flat price near $1.11, the reported volume of 12674, and the −4.35% change. Proprietary signals per the Butterfly Supply-Chain Graph: none.

Open Questions

  • What products or services does the company sell, and what is its revenue source given reported revenue of $0.0M in each period?
  • What explains the 52-week range of $1 - $83600, and what corporate or capital-structure events are behind it?
  • What are the cash and debt balances, given that these fields are N/A in the financials?
  • What is the basis for the reported FCF of $4.9M in FY 2025 alongside net income of $-1.1M, and what drove the swing from $-11.5M in FY 2024?
  • Who are the company's institutional holders and insiders, and what is the current trading activity behind the volume of 12674?

WOK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for WORK Medical Technology Group LTD (Class A) (WOK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to WOK Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

WOK Bull vs. Bear Conversation Board — What's Your Call at $1.00?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON WOK 🐻 50% BEARISH CONVICTION
1. Pick Your Side on WOK:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $1.19 (+8.2%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is WOK (D • RQD 51/100) a Buy at $1.10?

Welcome to the WOK (WORK Medical Technology Group LTD (Class A)) Roar Pit. Current RQD Composite is 51/100 (Roarable Sell — Underperform / Distribution Warning) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.87 (-20.9%)
Spot @ $1.10

Pump the brakes on WOK — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on WOK, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless WORK Medical Technology Group LTD (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.36 (+23.6%)
Spot @ $1.10

WOK cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on WOK, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $1.10 (52-wk range $1.00 - $83600.00), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%